IPSC earnings analysis
What we found in IPSC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted 10-Q does not provide current-quarter income statement, segment, or cash-flow figures, so revenue, margins, EPS, and free cash flow cannot be quantified from the available filing text. Liquidity consisted of $52.0 million of cash, cash equivalents, and restricted cash and $147.5 million of investments as of June 30, 2026. Management identified banking disruption and interest-rate sensitivity risks, while reporting no material changes to the risk factors in the 2025 Form 10-K; no quantitative guidance was provided.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- $199.5M cash and investments
- The company reported $52.0 million of cash, cash equivalents, and restricted cash as of June 30, 2026, plus $147.5 million of investments, providing a liquidity base for ongoing operations.
- Limited interest-rate exposure
- Management stated that its low-risk investment portfolio means changes in market interest rates would not have a material impact on financial condition or results of operations; investments totaled $147.5 million at June 30, 2026.
- Disclosure controls effective
- Management concluded that disclosure controls were effective at a reasonable assurance level as of June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Banking access risk
- Disruptions at financial institutions or in the financial-services industry could impair access to cash and cash equivalents. The company held $52.0 million of cash, cash equivalents, and restricted cash as of June 30, 2026.
- Interest income sensitivity
- Interest income is sensitive to U.S. interest-rate levels, with $147.5 million of investments exposed to changes in market rates, although management characterized the portfolio as low risk and the potential impact as not material.
- No new risk-factor changes
- The company stated that there were no material changes to the risk factors disclosed in its 2025 Form 10-K, so no new filing-specific risk-factor escalation was identified.
What they said about what is next.
No quantitative revenue or EPS guidance was provided in the extracted 10-Q. The filing does not include an explicit forward outlook.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- Century Therapeutics (IPSC) reported significant revenue decline in Q1 2026 due to the cessation of collaboration revenue from its partnership with Bristol-Myers Squibb. The company continues to show negative net income…
- 10-K · March 12, 2026
- Century Therapeutics (IPSC) positions itself as an iPSC-derived, allogeneic cell therapy company centered on proprietary Allo‑Evasion™ engineering and in‑house scalable manufacturing. The company has moved its beta…
- 10-Q · May 9, 2024
- Century Therapeutics reported collaboration revenue of $855,000 for the quarter and a net loss of $28,062,000 (net loss per share $0.45). Revenue declined from $1,720,000 in the prior-year quarter while EPS improved…
- 10-Q · November 9, 2023
- Century Therapeutics (IPSC) reported Q3 collaboration revenue of $148,000 (vs. $2,224,000 in Q3 2022) and a GAAP net loss of $32,720,000 (EPS -$0.55), with operating expenses of $35,774,000. Liquidity remains sizable —…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing IPSC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever